Newsroom

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma...

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer...

ROME--(BUSINESS WIRE)--Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris : ALMEX, ISIN IT0005450819) (« Mexedia » ou la « Société ») informe que le rapport de couverture analyste préparé par GBC AG – l’un des principaux cabinets indépendants de recherche financière en Allemagne –, élaboré dans le cadre d’une issuer-sponsored research, a été finalisé et est désormais publiquement disponible. Ce rapport fait suite à la reprise de la couverture analyste par GBC AG, précédemmen...

ROMA--(BUSINESS WIRE)--Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” o la “Società”) comunica che il report di analyst coverage predisposto da GBC AG – una delle principali società indipendenti di ricerca finanziaria in Germania –, sviluppato nell’ambito di un contesto di issuer-sponsored research, è stato completato ed è ora pubblicamente disponibile. Il report fa seguito alla riattivazione della copertura da parte di GBC AG, precedentemente comuni...

ROME--(BUSINESS WIRE)--Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer...

新加坡--(BUSINESS WIRE)--(美國商業資訊)-- 全球首屈一指的技術和資料供應商Intercontinental Exchange (NYSE:ICE)今日宣布，Nanhua Singapore Pte. Ltd. (Nanhua Singapore)已正式成為ICE Futures Singapore和ICE Clear Singapore的會員。憑藉這一雙重會員資格，Nanhua Singapore可展開自營業務和客戶業務的交易及結算操作。 Nanhua Singapore執行長Zheng Peiyuan表示：「我們欣然加入新加坡的ICE平台，成為會員後，Nanhua Singapore得以強化自身的交易和全球結算能力，為客戶擴大國際市場的投資機會。這一會員資格彰顯了我們對於提供可靠高效的服務、滿足客戶不斷變化的需求的承諾，我們期待在持續協助客戶實現全球業務成長的同時，深化與ICE的合作。」 ICE Futures Singapore和ICE Clear Singapore總裁兼營運長Maria Levanti表示：「我們欣然歡迎Nanhua Singapore加入...

新加坡--(BUSINESS WIRE)--(美国商业资讯)-- 全球领先的技术和数据提供商Intercontinental Exchange (NYSE:ICE)今日宣布，Nanhua Singapore Pte. Ltd. (Nanhua Singapore)已正式成为ICE Futures Singapore和ICE Clear Singapore的会员。凭借这一双重会员资格，Nanhua Singapore可开展自营业务和客户业务的交易及清算操作。 Nanhua Singapore首席执行官Zheng Peiyuan表示：“我们很高兴能加入新加坡的ICE平台，成为会员后，Nanhua Singapore得以强化自身的交易和全球清算能力，为客户拓展国际市场的投资机遇。这一会员资格彰显了我们对于提供可靠高效的服务、满足客户不断变化的需求的承诺，我们期待在持续助力客户实现全球业务增长的同时，深化与ICE的合作。” ICE Futures Singapore和ICE Clear Singapore总裁兼首席运营官Maria Levanti表示：“我们非常高兴欢迎Nanhua Singa...

LONDON--(BUSINESS WIRE)--  19-December-2025 Issue: Mitsubishi HC Capital UK Plc Series 952 XS3185370544 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 24-September-2025 Date To: 24-December-2025 Record Date: 23-December-2025 Value Date: 24-December-2025 Benchmark Rate: 4.08622% Margin: 0.95% Total Rate: 5.03622% Floor: 0% Number of Days: 90 Day Count: 30/360 (ICMA) Basic Rule Interest Frequency: Quarter...